Clinical trials: Interstitial Lung Fibrosis
Idiopathic Pulmonary Fibrosis
(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
The ARTEMIS-IPF study was conducted to determine if ambrisentan was effective in delaying disease progression and death in participants with idiopathic pulmonary fibrosis (IPF), to evaluate its safety, and to evaluate its effect…
- Trial name
- ARTEMIS-IPF (NCT00768300)
- Testing
- Ambrisentan
- Where
- 185 sites in United States, Argentina and 20 more
- Volunteers
- 494 people
- Sponsor
- Gilead Sciences
Pulmonary Fibrosis
Safety of Nintedanib in Real World in China
The main objective of this study is to evaluate the incidence rates of adverse drug reactions (ADRs) and fatal adverse events (AEs) among idiopathic pulmonary fibrosis (IPF) patients in China who initiate nintedanib during the…
- Trial name
- NCT05676112
- Testing
- nintedanib, pirfenidone
- Sponsor
- Boehringer Ingelheim
Pulmonary Fibrosis
Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects
This study aims to evaluate the interaction of oral HRS-9813 capsules with pirfenidone and nintedanib on the pharmacokinetics of healthy subjects.
- Trial name
- NCT07229716
- Testing
- HRS-9813 Capsule, Nintedanib Soft Capsules, Pirfenidone Tablets
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Idiopathic Pulmonary Fibrosis
A Proof of Mechanism Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This is a dose escalation/dose finding, double-blind, placebo-controlled, parallel study of GSK2126458 in subjects with IPF. The study is designed to explore a number of doses of GSK2126458 for engagement of pharmacology after…
- Trial name
- NCT01725139
- Testing
- GSK2126458
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- GlaxoSmithKline
Idiopathic Pulmonary Fibrosis (IPF)
TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis
This is a Phase 1, 4-part, randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-1058 inhaled solution.
- Trial name
- NCT04589260
- Testing
- TD-1058
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
To assess the safety of treatment with pirfenidone (up to 3600 mg/d) in patients with pulmonary fibrosis/idiopathic pulmonary fibrosis (PF/IPF).
- Trial name
- NCT00080223
- Testing
- Pirfenidone
- Where
- 27 sites in United States
- Volunteers
- 83 people
- Sponsor
- Genentech, Inc.
Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Rationale: LTI-03 is an experimental medication breathed into the lungs using an inhaler. It is being studied for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- NCT06968845
- Testing
- LTI-03, Dry Powder Inhaler
- Where
- 48 sites in United States, Australia and 5 more
- Volunteers
- 120 people
- Sponsor
- Rein Therapeutics
Pulmonary Fibrosis
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
The experimental drug CNTO 888 is currently being studied in cancer patients with solid tumors and this study is the first to use this drug for patients with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT00786201
- Testing
- CNTO 888 1 mg/kg, CNTO 888 5 mg/kg, CNTO 888 15 mg/kg
- Where
- 30 sites in United States, Belgium and 3 more
- Volunteers
- 126 people
- Sponsor
- Centocor, Inc.
Idiopathic Pulmonary Fibrosis
Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
The objectives of this study are to assess the safety and efficacy of treatment with pirfenidone 2403 milligrams per day (mg/d) compared with placebo in patients with idiopathic pulmonary fibrosis (IPF), to assess the safety and…
- Trial name
- NCT00287716
- Testing
- Pirfenidone
- Where
- United States
- Volunteers
- 435 people
- Sponsor
- Genentech, Inc.
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF) Patients: A Real-World Study
This is a cross-sectional study that will be conducted across Japan using an online patient-reported outcome questionnaire. This study tries to find out the attitudes toward and experiences of the emotional and/or social impact…
- Trial name
- NCT07743996
- Where
- Japan
- Volunteers
- 122 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants
This is a randomized, double-blind, placebo-controlled Phase 1 study of SAD (Part 1) and MAD (Part 2) of orally administered GNS-3545 in healthy adult subjects. The food effect will be assessed in one cohort in Part 1.
- Trial name
- NCT07225296
- Testing
- GNS-3545
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Genosco Inc.
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
The study consists of 2 parts: Part A is a randomized, multiple-dose, double-blind, placebo-controlled sequential dose escalation study to evaluate GS-6624 in subjects with Idiopathic Pulmonary Fibrosis (IPF) and was completed in…
- Trial name
- NCT01362231
- Testing
- GS-6624
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Gilead Sciences
Idiopathic Pulmonary Fibrosis
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis (IPF).
- Trial name
- ZAPPHIRE (NCT07516951)
- Testing
- CHF10067
- Where
- 19 sites in United States, North Macedonia and 2 more
- Volunteers
- 240 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
This is an open-label extension study for participants who were previously enrolled in and completed an Avalyn Pharma Sponsored study with an inhaled antifibrotic, such as AP01.
- Trial name
- SAIL (NCT06951217)
- Testing
- AP01
- Where
- 85 sites in United States, Argentina and 11 more
- Volunteers
- 340 people
- Sponsor
- Avalyn Pharma Inc.
Idiopathic Pulmonary Fibrosis
Dose Reduction and Discontinuation With Anti-Fibrotic Medications
The overarching aim of our study is to assess the incidence of dose reduction and discontinuations for pirfenidone and nintedanib.
- Trial name
- NCT05779007
- Testing
- Pirfenidone, Nintedanib
- Where
- United States
- Volunteers
- 2,778 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis (IPF)
Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis
This is a multicenter, Phase II clinical study to evaluate the efficacy and safety of BC006 over a 24-week treatment period in patients with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT07447102
- Testing
- BC006
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Dragonboat Biopharmaceutical Company Limited
Idiopathic Pulmonary Fibrosis
A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
The goal of this clinical trial is to learn about the potential effect of ENV-101 (taladegib) on the pharmacokinetics of nintedanib (an approved treatment for idiopathic pulmonary fibrosis) when the two compounds are dosed…
- Trial name
- NCT05817240
- Testing
- taladegib, nintedanib
- Where
- Australia
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Endeavor Biomedicines, Inc.
Lung Diseases, Interstitial
An Expanded Access Program in Belgium to Provide Nintedanib to People With Lung Diseases Called Non-IPF ILDs Who Have no Alternative Treatment Options
This Expanded Access Program in Belgium is open to people with different lung diseases. This program provides a medicine called nintedanib to people who have no alternative treatment options.
- Trial name
- NCT04739150
- Testing
- nintedanib
- Where
- 14 sites in Belgium
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/
A study in mild/moderate IPF patients using an αVβ6 PET ligand to evaluate target engagement.
- Trial name
- IPF-201 (NCT04072315)
- Testing
- PLN-74809, Knottin tracer
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Pliant Therapeutics, Inc.
Idiopathic Pulmonary Fibrosis
A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects
This study is being conducted to evaluate the safety and tolerability of single ascending and multiple ascending oral doses of NIP292 tablets administered following an overnight fast in healthy adult subjects.
- Trial name
- NCT04720443
- Testing
- NIP292 tablet, NIP292 tablets
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- The National Institutes of Pharmaceutical R&D Co. Ltd, China